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Summary.-Multicellular tumour spheroids of the EMT6 mouse tumour line have
been grown in a static (i.e. non-spinner) culture system to a mean spheroid diameter
of 250 ,um. Samples of spheroids were then exposed for 1 h to graded concentrations
of various cytotoxic drugs, and the response assayed by both growth delay and sur-
vival of clonogenic cells. For nitrogen mustard (HN2), melphalan, BCNU, CCNU
and cis-platinum, a considerable recovery in measured cell survival was seen if
the clonogenic assay was delayed for 24 h after drug exposure. A reasonably good
correlation between growth delay and cell survival (measured at 24 h) was observed
for these 5 agents. For adriamycin, actinomycin D and 5-fluorouracil, no increase in
measured cell survival was seen for a 24h delay in assay, and these agents produced
longer growth delays for a given level of cell kill.
THE MULTICELLULAR tumour-spheroid
model system, in which cells grow in vitro
as 3-dimensional aggregates, represents
an intermediate level of complexity be-
tween cells growing as monolayers in vitro
and solid tumours in experimental animals
(Suitherland & Durand, 1976; Yuhas et al.,
1977). Recent studies have demonstrated
that the relationship between tumour
growth delay and clonogenic cell survival
after radiotherapy (McNally & de Ronde,
1980) or chemotherapy (Twentyman, 1980)
of animal tumours is very complex. Espec-
ially in the case ofchemotherapy, in which
the treatment is given systemically, altera-
tion ofthe host mayhave an important role
in the determining of the response of the
in situ tumour (Brown, 1979). Using the
spheroid model system, however, it is
possible to study the relationship between
growth delay and cell survival in the
absence ofthese host effects. In this paper,
experiments are described in which the
response to a range of cytotoxic drugs has
been studied in spheroids of the EMT6/
Ca/VJAC mouse tumour cell line.
MATERIALS AND METHODS
The cells used in these studies were of the
EMT6/Ca/VJAC subline of the EMT6 mouse
tumour described initially by Rockwell et al.
(1972). (This subline has previously been
designated EMT6/VJ/AC but has been re-
designated to conform with a convention
agreed amongst users of the EMT6 system.)
This line is maintained by successive
growth as a solid tumour in mice of
the BALB/c strain and as a monolayer in
vitro. Cells used for spheroid initiation in
these studies were taken from the 2nd to
the 6th in vitro passage since previous in vivo
growth.
The medium used throughout was Eagle's
MEM with Earle's salts, supplemented witlh
10% foetal calf serum (both Gibco Biocult
Ltd) with antibiotics. Our technique for
initiation and growth ofspheroids was closely
based on that of Yuhas et al. (1977). Tissue-
culture flasks (75 em2, Sterilin Ltd), plastic
universal containers (Sterilin Ltd) and plastic
tissue-culture multidishes (Linbro) were pre-
pared with a base-coat of complete medium
containing 0.75%o Noble Agar (Difco). Vol-
umes of agar-containing medium were 10 ml
in 75cm2 flasks, 2 ml in universal tubes, andP. R. TWENTYMAN
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0(5 ml into each 1-6 cm2 well on a 6 x 4-well
multidish.
The experimental protocol for spheroid
growth and drug response experiments is
summarized in Fig. 1. To initiate spheroid
growth, 5x 105 cells, trypsinized from a
monolayer, were placed in a volume of 15 ml
of complete medium into each agar-coated
75 cm2 flask. The flasks were gassed with 5%
CO2 in air and incubated at 370 C for 4 days.
The liquid medium containing the growing
spheroids was then removed with a pipette
and placed into a plastic universal tube. After
a few minutes, the bulk of the medium was
removed, leaving the spheroids at the bottom
of the tube in a volume of about 0 5 ml of
residual medium. The spheroids were then
resuspended in 15 ml of fresh medium and
transferred to a new agar-based flask (the
original flask was not re-used because of the
presence of a monolayer of cells on the base
of the flask below the agar. These were the
progeny of cells which had passed down the
side of the agar at the initial inoculation).
Next day this process was repeated, with the
difference that the resuspended spheroids
were replaced into the flask from which they
had been taken. Spheroids were then used on
Day 6 for drug treatment.
Spheroids from 2-3 flasks were pooled and
a number of glass universal tubes were pre-
pared, each containing 5 x 103 spheroids,
mean diameter 250 ,tm (see Results section)
in 10 ml of fresh medium. Cytotoxic drugs
were added to the tubes in volumes of
between 0 04 and 0-2 ml. The drugs and
solvents used are shown in Table I. Pre-
liminary experiments were carried out to
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tocol for drug-response experiments.
TABLE I.-Cytotoxic drugs studied
Name ofdrug
(abbreviation)
Nitrogen mustard
(Mustine hydro-
chloride) (HN2)
1,3-bis (2-
chloroethyl)-I-
nitrosourea
(BCNU)
1-(2-chloroethyl)-
3-cyclohexyl-l-
nitrosourea
(CCNU)
cis-Diamine-
dichloro
platinum (II)
(CIS-P)
Melphalani
(MELPH)
Adriamycin
(ADM)
Actinomycin-D
(ACT-D)
5-fluorouracil
(5FU)
Supplier
Boots Co. Ltd.,
Nottingham
Drug Development
Branch, Division
ofCancer
Treatment, U.S.
National Cancer
Institute
Lundbeck Ltd.,
Luton
Solvent
used
Complete
medium
Absolute
ethanol
Absolute
ethanol
Drug Development Normal
Branch, Division saline
ofCancer
Treatment, U.S.
National Cancer
Institute
Burroughs Wellcome Acidified
Co., London ethanol
Pharmitalia Ltd., Distilled
Italy water
Merck, Sharp & Distilled
Dohme, Rahway, water
New Jersey, USA
Roche Ltd.,
Welwyn Garden
City
Distilled
water
confirm that 0-2 ml of any of the solvents
alone caused no significant growth delay or
cell killing. The tubes were then incubated at
37°C for 1 h with intermittent agitation. At
the end of this time, the spheroids were
allowed to settle and were then twice rinsed
with 10 ml of fresh medium. Each group of
spheroids was then resuspended in 5 ml and
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subdivided into 3 portions for different assays
ofresponse:
Growth delay.-I ml of medium containing
spheroids was placed into a 5 cm-diameter
plastic Petri dish (Sterilin Ltd) and 4 ml of
complete medium added. A Pasteur pipette
was then used to transfer individualspheroids
to agar-coated wells on plastic tissue-culture
multidishes with I spheroid per well. Twelve
spheroids -were taken from each treatment
group. One ml ofcomplete medium NN-as added
to each well. The NN-ells -%Aere then examined
under an inverted microscope at x 40 and
two diameters at right angles %A-ere measured
with an eye-piece graticule which had been
previously calibrated. Spheroids were subse-
quently measured 3 times weekly and the
medium in each well -,Nas changed twice
weekly.
Cell sui-vival (iminediate).-2 ml of medium
containing spheroids was transferred to a
plastic universal tube with a conical base.
The spheroids were allowed to settle and the
medium removed. Tm-o ml of a 0-075%
trypsin solution in PBS (Gibco Biocult) Avas
added, the s-phei-oids again allowed to settle
and the solution removed. A further 2 ml of
trypsin solution -NN-as added and the tube then
incubated for 15 min at 37'C, after -which the
trypsin solution was again removed and 1-5
ml of complete medium added. A Pasteur
pipette NN-as then used to draw the spheroids
up and down several times, causing them to
disintegrate into a single-cell suspension. In a
number of experiments. spheroids were dis-
aggregated Nvith either trypsin or bacterial
neutral protease (Twentyman & Yuhas, 1980)
in order to study whether the technique of
disaggregation could influence the surviving
fraction. The cells were counted on a haema-
cytometer, appropriate dilutions made and
various numbers of cells -were plated into
9cm tissue-culture Petri dishes, (Sterilin Ltd)
containing 11 ml of complete medium. The
dishes were then incubated for 9 days at
37'C in an atmosphere of5% C02 in air. The
dishes -were, then rinsed in saline, fixed in
alcohol and stained NN-ith a solution ofcrystal
violet. Colonies of 50 or inore cells -%vere
counted -with a binocular dissecting micro-
scope.
Cell survival (24h delay).-2 ml of medium
containing spheroids was placed into a plastic
universal tube which had been base coated
Nvith agar. An additional 8 ml of mediumwas
added, and the tube incubated for 24 h at
37'C, when the spheroids Nvere disaggregate(I
and cell-survival assayed as above.
RESULTS
Frequency ofmedium change
EMT6/Ca/VJAC
day 4
(A
.51-
4)
CL
V)
4-
3.0
4)
.0
E
z In order to determine whether the
growth curve of individual spheroids in
wells was likely to be affected by the
frequency of medium change, an experi-
ment was conducted whereby spheroids of
mean diameter - 400 tim were placed into
wells. Spheroid size was measured daily
=4 for 6 days with various groups baving the
600 medium changed daily, every 2nd day, on
the 4th day only, or not at all. All groups
reached a mean diameter of -9.00 /im on
froi-n Day 6, with no significant difference be-
tween them. It was therefore concliided
Spheroid diameter (Itm)
FiG. 2.-Histograms ofsplieroi(i size (iist
tion at x-ai-lotis times after iiiltlation
single cells.P. R. TWENTYMAN
difference between the times for the
treated group and the control group to
reach twice its own mean initial diameter.
In general, growth delays of more than 10
days were not seen, but in groups which
did not regrow, the spheroids remained
intact at around the initial volume for at
least 20 days. Selected growth delays for
all drugs studied are shown in Table II.
Cell survival
For 5 of the agents studied (HN2,
BCNU, CCNU, MELPH and CIS-P) the
survival curves had similar shapes, with
an initial shoulder giving way to an
exponential fall. In each case, delay of
disaggregation by 24 h led to a marked
reduction in the slope of the curve. The
data for 2 experiments using MELPH are
shown in Fig. 4. Interpolated values, read
offfrom best lines fitted by eye to the data
for these 5 agents, are shown in Table III.
It may be seen that rather similar values
TABLE II.-Spheroid growth delay induced
by Ih exposure to various drugs
Dai
FIG. 3. Grow thi curxves for EMT6 spheroids
treated on Day 0 with ACT-D or MIEI,L'H.
P'oints show% the mean splheroid (liameter for
groups of 12 splieroids and: error bars are
950 confidlence limits. (Omitted fiom some
ofthe (lata for clarity.)
that twice-weekly medium change would
be adequate during regrowth experiments.
Spheroid size distribution
After flasks of spheroids with 5 x 105
cells had been set up on Day 0, the size
distribution of spheroids was determined
on Days 4, 5, 6 and 7, with a flask change
on Day 4 and daily medium change there-
after. The results are shown in Fig. 2. On
Day 6, the mean spheroid diameter was
249 +61( um (s.d.).
Growth delay
Two typical sets of growth-delay data
are shown in Fig. 3. The growth delay for
each treated group was taken as the
Dose
Agent ( tg/ml)
HiN2 0'3
0 6
()
B3CNU 3
6
8
CCNU :3
5
9
CIS-P
AIELPH
ADAT
ACT-D
5FU
10
15
5
8
11
3
6
9
6
12
18
20
40
60
C--
2 3;
4-4;
6-5;
13;
2-6;
(5-8);
0.0;
16;
4-2;)
1*5;
4-0;
10-8;
1]6;
(3.0);
(5-1);
0-8;
1 8;
2-3;
2-7-
5-5;
7-2;
4-1 ;
5-33;
6-5;
Gro
(3.5);
(63);
(80);
05;
1-4;
2 8;
0 8
2-4
3-9
(1-1);
3-7
6-1
10;
3.3
7-5
1]6;
2-4;
(3-5)
2-7-
1-3;
)wtih (lelay
(days)
2-3; (1-
4-3; (3
(5.
0 7; (0
2-9; 3
4-7; 4.
.9); 2-5
9); 6-6
3); (9.0)
*7)
4
2-:3
().1
3-.9
3.7
(2'5); (3.9)
4-1
(5-6)
:3-1
For each drug, figures in the same vertical column
are from the same experiment.
Figures in brackets are interpolatc(l Xalues.
.- .1
.:L .-
.1
0
a.0
I ..
.
I.
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TABLE III. Measured d
in spheroids exposed J
agents
Dose
Agent (fig/ml)
HN2 0 40
0-83
BCNU 3-6
7-8
CCNU 3 6
7-8
CIS-P 6-0
12-1
MELPH 5.0
9-6
A
Surviving
fraction
(imme-
diate)
4x 10-2
10-3
4 x 10- 2
10-3
4 x 10-2
10-3
4 x 10-2
10-3
4x 10-2
10-3
Surviving fraction -alues ar
fitted by eye to the data poiI
indepen(leiit expeiiments.
Dose
n0
c
iL .2
.
v)
10o-
10-2
5
0
iurviving fractions for the recovery factors are seen, from the
for 1 h to various same level of initial survival, for all 5
agents.
B The pattern for the other 3 agents was
fractiong Recoery uite different. The results for ADM are
(24 lh factor shown in Fig. 5. It may be seen that there
delay) (B/A) was no significant difference in the meas-
2-2 x 10-1 19 ured cell survival between immediate and
29 X 10x 19 73 delayed plating, and that survival was 4-7 x 10-2 47-3 still up at around 20% for a dose of 10 ,ug/
3-5 x 10-1 8-8 ml. A similar response was seen for 5-
45 x 10-2 450 fluorouracil, where the cell survival was
30x 10-1 7.5 still >40%0 at a dose of 40 zg/ml. For 3-8 x 10-2 38-0 actinomycin D, 2/3 experiments showed a
2.1 x 10-1 5 3 rather lower value ofsurviving fraction by
:3-3x10-2 33-0
a factor of 2-3 at 24 h than at immediate
e read from the lines assay at doses above 10 ,ug/ml. In the third
ltS from at least twso experiment values were similar for the two
times of assay.
(rag/ml) In these experiments, it is difficult pre-
10 15 cisely to quantify changes in cell yield for
a group of spheroids during the 24 h after
treatment. This is largely because of the
difficulty in maintaining even dispersion
of the spheroids in the medium when
taking equal volumes just before drug
exposure. For none ofthe drugs, however,
was there a detectable reduction in cell
yield 24 h after treatment, with the ex-
ception ofACT-D, with which a consistent
A decrease in yield by a factor ofabout 2 was
found. Furthermore, all the individual cell
24h Try yields for groups of spheroids, whether for Delay immediate or delayed disaggregation,
Immed
Tryp lo-,
0
to U.
A._
U)
A
FIG. 4. (liange in surviving fraction of
clonogenic cells in spheroids treated for 1 Ii
with (lifferent concentrations of AIELPH.
Closed symbols: disaggregation and clono-
genic assay carried out immediately after
(crug exposure. Open symbols: spheroids
held intact, for 24 1h after clrug exposure and
before disaggregation an(c clonogenic assay.
Triangles an(d circles are independent
experiments.
Dose (Big/mi)
? 0;2 0;4 0:6 0 1,0
0*7-
0-4-
0
A
O *~ A
0
*°-
A
A
g m
FIG. 5. Chlange in surviving fraction of
clonogenic cells in spheroids treated for 1 h
with (lifferent concentrations of ADM.
Otherwise as Fig. 4.
21
1-U 6s I- ,,
I." 1--
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were generally within a factor of 2 of each
other.
Methods ofdisaggregation
Survival curves for immediate dis-
aggregation were obtained after HN2,
ADM and BCNU, using either trypsin or
neutral protease as the enzyme. In each
case the results obtained appeared in-
dependent of the enzyme used, and the
plating efficiency for cells from untreated
spheroids was similar: between 55 and
70%.
Comparison ofendpoints
In order to study the relationships
14L--2- - - . .X ., .,.__ _ .. * .~-i =,--N- :
C.,:- I......
w. -V i
at+ ..-,;My'a
Nb
j..! ..
FIG. 6.-Plot of spheroid growth delay vs
clonogenic cell survival with disaggregation
and assay carried out immediately after
drug exposure. Each point is taken from an
experiment in which both assays were
carried out on spheroids from the same
treatment group. 0 HN2; A BCNU;
*-CCNU; V-CIS-P; *-MELPH;
A ADM; O-ACT-D; O 5FU. The
lines show where points would be expected
to lie if the doubling time of the surviving
clonogenic cells were as indicated. The
assumptions upon which these times are
calculated are given in the RESULTS
section.
:tS~~~~~~~~: X:: \000\0077770:Eu 77"
FIG. 7.--As Fig. 6, but disaggregation and
assay carried out 24 h after drug exposure.
between endpoints, the data for spheroid
growth delay have been plotted against
the measured cell survival, either immedi-
ately after drug treatment (Fig. 6) or with
a 24h delay in disaggregation (Fig. 7). In
each case, lines have been drawn to indi-
cate where the points would be expected
to lie for various values of the doubling
time (TD) of surviving clonogenic cells,
using the relationship
TD= log 2 xgrowth delay -log surviving fraction'
It is assumed that (a) proliferation of
surviving clonogenic cells begins immedi-
ately after treatment, (b) the surviving
cells maintain the given doubling time
until the time at which the extrapolation
backwards of the regrowth crosses the
initial mean diameter, and (c) the growth
kinetics during the period between the
time at which the extrapolation back-
wards of the regrowth curve crosses the
initial mean diameter and the time of
reaching twice the initial mean diameter
are the same as those in untreated
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spheroids over the same change in dia-
meter (in most cases the spheroid re-
growth curves after drug treatment are
parallel to the untreated regrowth curve.
There are, however, exceptions to this
rule (e.g. after 15 ,ug/ml of Melphalan,
Fig. 3).
In Fig. 6, it may be seen that there is a
clear separation between the points for
ACT-D, ADM and 5FU and those for the
other 5 agents studied. For the first 3
agents, growth delays of 4-8 days are
associated with less than 1 log of cell
killing, resulting in calculated doubling
times > 48 h. For BCNU and CCNU, on
the other hand, indicated doubling times
of less than 6 h are obtained at low doses
and 6-12 h at higher doses. For CIS-P
and MELPH, values generally lie at
6-12 h, whereas for HN2 a doubling time
of 12-18 h is indicated.
When surviving fractions are measured
at 24 h after drug treatment (Fig. 7), it is
still apparent that ACT-D, ADM and
5FU produce longer growth delays for a
given amount of cell kill than do the other
drugs. For the other 5 agents, however,
the points have all moved towards longer
indicated doubling times because of the
higher measured values of cell survival
with delayed assay. There are now very
few points to the left of the line corres-
ponding to a doubling time of 12 h and the
great majority of points lie between the
lines corresponding to doubling times of
12 and 24 h, with a tendency towards
larger doubling times for smaller surviving
fractions.
DISCUSSION
The description by Yuhas et al. (1978)
of how spheroid growth delay in a static
(i.e. non-spinner) culture system can be
used as a response endpoint has opened up
many interesting applications of multi-
cellular tumour spheroids in vitro. This is
especially true in view of a number of
observations that a wide variety oftumour
cell types of both animal and human
origin will grow in this way (Yuhas et al.,
1977; Haji-Karim & Carlsson, 1978). It is
important, however, to consider how this
growth delay endpoint is related, for
various agents, to the level of survival of
clonogenic cells.
It is clear from these results that for the
EMT6 spheroid system, as it is for the
EMT6 solid murine tumour, time of assay
is an extremely important factor in the
measurement of cell survival and that
apparent "recovery from potentially lethal
damage" occurs after treatment with
various cytotoxic drugs (Twentyman,
1979; Begg et al., 1980). The possibility
that this effect in the solid tumour may be
in some way dependent on the presence of
host cells within the tumour can now
however be discarded. The possibility
remains that the surviving fractions
measured immediately after drug treat-
ment are artificially low, owing to an
interaction between drug and trypsin
damage. The fact that similar values of
cell survival are obtained using either
trypsin or bacterial neutral protease dis-
aggregation would, however, argue against
this idea. Bacterial neutral protease has
been seen to cause much less damage to
the cell membrane than conventional
trypsin regimes (Matsumara et al., 1975).
From the data presented in Fig. 6, the
calculated doubling times for many of the
points are unrealistically short. Doubling
times for various sublines of EMT6 cells
in exponential culture have been in the
region of 12- 4 h (Twentyman et al., 1975;
Begg et al., 1980) and it seems unlikely
that the doubling times in regrowing
spheroids would be any shorter than this.
It appears, therefore, that the surviving
fractions measured immediately after drug
treatment do not, for many drugs, reflect
the degree ofdamage which determines the
regrowth of intact spheroids. If however
measurement of cell survival is delayed
until 24 h after drug treatment, the cal-
culated doubling times become more
reasonable (Fig. 7), most points for
BCNU, CCNU, CIS-P, MELPH and HN2
corresponding to values of 12-24 h. There
appears to be a tendency for the indicated
doubling time to increase at lower levels of
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survival, and to be very short when killing
is only by one order of logs. This is what
would be predicted if the growth kinetics
of regrowing spheroids did not return to
control patterns until they were consider-
ably larger than the treatment size
(Twentyman, 1980) and it supports the
idea of Stephens & Peacock (1977) that
this is what happens in at least some
mouse tumours after drug treatment.
Despite these limitations, however, the
data in Fig. 7 show a reasonably good
correlation between growth delay and cell
survival measured at 24 h for the 5 drugs
mentioned above. For ACT-D, 5FU and
ADM the indicated doubling times are
longer than for the other agents. The
results of Begg et al. (1980) for the EMT6/
SF solid tumour led to a similar conclusion
for ACT-D and 5FU. In that work, drug
effects upon the tumour-bearing host were
mentioned as a possible complicating
factor, but this is clearly not a considera-
tion in the spheroid model. An additional
explanation is that these agents (and
ADM) are able to produce considerable
cell-cycle delay in addition to cell killing.
That this is true for ADM is strongly sup-
ported by observations in other tumour
systems (Dethlefsen et al., 1979; Rowley
et al., 1979).
These studies are at present being ex-
tended toother tumour cell lineswhich will
grow both as colonies from single cells and
as spheroids in static culture, in order to
see whether the conclusions reached for
the EMT6 system are generally applicable.
At the same time we are trying to initiate
spheroid growth from clinical tumour
material, with the eventual objective of
using spheroid growth delay as an assay
for chemosensitivity.
I thank Kim Bowden, Daryl Knight and Karen
Wright for their excellent technical assistance.
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